{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:57:02Z","timestamp":1782845822084,"version":"3.54.5"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.clineuro.2021.106893","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T18:30:36Z","timestamp":1628879436000},"page":"106893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6193-6871","authenticated-orcid":false,"given":"Prashant","family":"Soni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanka","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.clineuro.2021.106893_bib1","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","article-title":"Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"16","author":"GBD Neurological Disorders Collaborator","year":"2017","journal-title":"Lancet Neurol."},{"issue":"10100","key":"10.1016\/j.clineuro.2021.106893_bib2","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"GBD Disease and Injury Incidence and Prevalence","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clineuro.2021.106893_bib3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jns.2016.11.071","article-title":"Migraine affects 1 in 10 people worldwide featuring recent rise: a systematic review and meta-analysis of community-based studies involving 6 million participants","volume":"372","author":"Woldeamanuel","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.clineuro.2021.106893_bib4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-pharmtox-010814-124701","article-title":"Calcitonin gene-related peptide (CGRP): a new target for migraine","volume":"55","author":"Russo","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.clineuro.2021.106893_bib5","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of migraine: a disorder of sensory processing","volume":"97","author":"Goadsby","year":"2017","journal-title":"Physiol. Rev."},{"issue":"8","key":"10.1016\/j.clineuro.2021.106893_bib6","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/head.13588","article-title":"Unmet acute treatment needs from the 2017 migraine in America symptoms and treatment study","volume":"59","author":"Lipton","year":"2019","journal-title":"Headache J. Head Face Pain"},{"issue":"6","key":"10.1016\/j.clineuro.2021.106893_bib7","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1177\/0333102411398399","article-title":"Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine","volume":"31","author":"Hewitt","year":"2011","journal-title":"Cephalalgia"},{"issue":"2","key":"10.1016\/j.clineuro.2021.106893_bib8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/0333102413500727","article-title":"BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial","volume":"34","author":"Marcus","year":"2014","journal-title":"Cephalalgia"},{"issue":"11","key":"10.1016\/j.clineuro.2021.106893_bib9","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa030505","article-title":"Calcitonin gene\u2013related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine","volume":"350","author":"Olesen","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.clineuro.2021.106893_bib10","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1177\/0333102416653233","article-title":"A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine","volume":"36","author":"Voss","year":"2016","journal-title":"Cephalalgia"},{"issue":"10200","key":"10.1016\/j.clineuro.2021.106893_bib11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","article-title":"Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial","volume":"394","author":"Croop","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.clineuro.2021.106893_bib12","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.2019.16711","article-title":"Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial","volume":"322","author":"Lipton","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.clineuro.2021.106893_bib13","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/bcp.12591","article-title":"Therapeutic antibodies against CGRP or its receptor","volume":"79","author":"Bigal","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.clineuro.2021.106893_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1215","article-title":"CGRP monoclonal antibody for preventive treatment of chronic migraine: an update of meta\u2010analysis","volume":"9","author":"Han","year":"2019","journal-title":"Brain Behav."},{"issue":"1","key":"10.1016\/j.clineuro.2021.106893_bib15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s10194-017-0750-1","article-title":"The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis","volume":"18","author":"Hou","year":"2017","journal-title":"J. Headache Pain"},{"issue":"14","key":"10.1016\/j.clineuro.2021.106893_bib16","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.3390\/ijms20143527","article-title":"Effects of anti-calcitonin gene-related peptide for migraines: a systematic review with meta-analysis of randomized clinical trials","volume":"20","author":"Huang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.clineuro.2021.106893_bib17","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1177\/0333102419829007","article-title":"Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine\u2013a meta-analysis of randomized controlled trials","volume":"39","author":"Xu","year":"2019","journal-title":"Cephalalgia"},{"issue":"12","key":"10.1016\/j.clineuro.2021.106893_bib18","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s10072-018-3547-3","article-title":"The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis","volume":"39","author":"Zhu","year":"2018","journal-title":"Neurol. Sci."},{"issue":"1","key":"10.1016\/j.clineuro.2021.106893_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-020-01633-3","article-title":"Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine\u2013an updated systematic review and meta-analysis","volume":"20","author":"Deng","year":"2020","journal-title":"BMC Neurol."},{"issue":"11","key":"10.1016\/j.clineuro.2021.106893_bib20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"9","key":"10.1016\/j.clineuro.2021.106893_bib21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1177\/0333102413485658","article-title":"The international classification of headache disorders, (beta version)","volume":"33","author":"Olesen","year":"2013","journal-title":"Cephalalgia"},{"key":"10.1016\/j.clineuro.2021.106893_bib22","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.2147\/PPA.S182563","article-title":"Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine","volume":"12","author":"Ford","year":"2018","journal-title":"Patient Prefer. Adherence"},{"issue":"10203","key":"10.1016\/j.clineuro.2021.106893_bib23","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clineuro.2021.106893_bib24","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.clineuro.2021.106893_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.clineuro.2021.106893_bib26","unstructured":"R-4.0.0 for Windows (32\/64 bit). \u3008https:\/\/cran.r-project.org\/bin\/windows\/base\/\u3009."},{"key":"10.1016\/j.clineuro.2021.106893_bib27","unstructured":"MRC Biostatistics Unit. OpenBUGS. \u3008https:\/\/www.mrc-bsu.cam.ac.uk\/software\/bugs\/openbugs\/\u3009."},{"issue":"5","key":"10.1016\/j.clineuro.2021.106893_bib28","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med. Decis. Mak."},{"issue":"10","key":"10.1016\/j.clineuro.2021.106893_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clineuro.2021.106893_bib30","series-title":"Bayesian Approaches to Clinical Trials and Health-care Evaluation","author":"Spiegelhalter","year":"2004"},{"issue":"4","key":"10.1016\/j.clineuro.2021.106893_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/cc9182","article-title":"Updating the evidence for the role of corticosteroids in severe sepsis and septic shock: a Bayesian meta-analytic perspective","volume":"14","author":"Moran","year":"2010","journal-title":"Crit. Care"},{"issue":"6","key":"10.1016\/j.clineuro.2021.106893_bib32","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.clineuro.2021.106893_bib33","unstructured":"S. Dias, N.J. Welton, A.J. Sutton, D.M. Caldwell, G. Lu, A. Ades, NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials, 2011."},{"issue":"1","key":"10.1016\/j.clineuro.2021.106893_bib34","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-018-1193-2","article-title":"A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine","volume":"18","author":"Camporeale","year":"2018","journal-title":"BMC Neurol."},{"issue":"Supplement 1","key":"10.1016\/j.clineuro.2021.106893_bib35","first-page":"23","article-title":"Clinically meaningful responses to fremanezumab in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive medications in the multicenter, randomized, placebo-controlled focus study","volume":"59","author":"Spierings","year":"2019","journal-title":"Headache"},{"issue":"Supplement","key":"10.1016\/j.clineuro.2021.106893_bib36","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jns.2019.10.338","article-title":"Odds ratios for response to fremanezumab in migraine patients with inadequate response TO 2-4 migraine preventive medication classes: results of the focus phase 3B study","volume":"405","author":"Diener","year":"2019","journal-title":"J. Neurol. Sci."},{"issue":"Supplement 1","key":"10.1016\/j.clineuro.2021.106893_bib37","first-page":"798","article-title":"Reduction in the number of headache hours and days with fremanezumab in patients with migraine and documented inadequate response to 2-4 migraine preventive medications in the international, multicentre, randomised, placebo-controlled FOCUS study","volume":"26","author":"Karppa","year":"2019","journal-title":"Eur. J. Neurol."},{"issue":"Supplement 1","key":"10.1016\/j.clineuro.2021.106893_bib38","first-page":"803","article-title":"Impact of fremanezumab on symptoms associated with migraine in patients with documented inadequate response to 2-4 classes of migraine preventive medications in the international, multicentre, randomised, placebocontrolled FOCUS study","volume":"26","author":"McAllister","year":"2019","journal-title":"Eur. J. Neurol."},{"issue":"1 Supplement","key":"10.1016\/j.clineuro.2021.106893_bib39","first-page":"223","article-title":"Impact of fremanezumab on migraineassociated symptoms in patients with documented inadequate response to 2-4 classes of migraine preventive medications in the international, multicentre, randomised, placebo-controlled focus study","volume":"39","author":"McAllister","year":"2019","journal-title":"Cephalalgia"},{"issue":"1 Supplement","key":"10.1016\/j.clineuro.2021.106893_bib40","first-page":"223","article-title":"Clinically meaningful responses to fremanezumab in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive medications in the international, multicentre, randomised, placebo-controlled focus study","volume":"39","author":"Spierings","year":"2019","journal-title":"Cephalalgia"},{"issue":"Supplement 3","key":"10.1016\/j.clineuro.2021.106893_bib41","first-page":"197","article-title":"Chronic migraine treatment with erenumab: responder rates","volume":"57","author":"Brandes","year":"2017","journal-title":"Headache"},{"issue":"6","key":"10.1016\/j.clineuro.2021.106893_bib42","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol."},{"issue":"7829","key":"10.1016\/j.clineuro.2021.106893_bib43","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1038\/d41586-020-02862-9","article-title":"A new generation of headache drugs","volume":"586","author":"Woo","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.clineuro.2021.106893_bib44","unstructured":"P. McAllister, What the Neurologist Needs to Know, 2017."},{"key":"10.1016\/j.clineuro.2021.106893_bib45","unstructured":"A. Ibekwe, C. Perras, M. Mierzwinski-Urban, Monoclonal antibodies to prevent migraine headaches, 2019."},{"issue":"1","key":"10.1016\/j.clineuro.2021.106893_bib46","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s10194-016-0703-0","article-title":"Network meta-analysis of migraine disorder treatment by NSAIDs and triptans","volume":"17","author":"Xu","year":"2016","journal-title":"J. Headache Pain"}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846721004224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846721004224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:38:12Z","timestamp":1759588692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846721004224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":46,"alternative-id":["S0303846721004224"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2021.106893","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2021.106893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106893"}}